Contact
Please use this form to send email to PR contact of this press release:
Reata Announces Primary Results from the Phase 2 CARDINAL Study of Bardoxolone in Alport Syndrome at the American Society of Nephrology Kidney Week 2017 Annual Meeting
TO: